Clinical and biological characteristics according to mHLA-DR at D−7 before anti-CD19 CAR T-cell infusion
| . | mHLA-DR <13 500 Ab/c (n = 10) . | mHLA-DR ≥13 500 Ab/c (n = 77) . | P∗ . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 60 (48-74) | 60 (27-77) | .02 |
| Mean (95% CI) | 65.5 (59.1-71.3) | 56.6 (53.9-59.3) | |
| >65 | 7 (70) | 21 (27) | .01 |
| Sex | |||
| Male sex | 7 (70) | 46 (60) | .73 |
| Female sex | 3 (30) | 31 (40) | — |
| Cell of origin | |||
| GCB | 6 (60) | 35 (56) | >.99 |
| Non-GCB | 4 (40) | 27 (44) | |
| B symptoms | 3 (30) | 6 (8) | .07 |
| ECOG PS | |||
| 0-1 | 5 (50) | 67 (87) | .01 |
| 2-3 | 5 (50) | 10 (13) | |
| Ann Arbor stage | |||
| I-II | 0 | 19 (25) | .11 |
| III-IV | 10 (100) | 58 (75) | |
| MTV D−7, mL | |||
| Median (IQR) | 114.4 (76.1-696.6) | 35.6 (5.8-116.7) | .02 |
| >80 mL | 5 (83) | 14 (30) | .02 |
| >100 mL (reported in JULIET trial) | 3 (50) | 13 (28) | .35 |
| LDH | |||
| >ULN | 9 (90) | 49 (64) | .15 |
| >2 ULN | 7 (70) | 5 (5) | <.0001 |
| Lines of therapy before leukapheresis, n | |||
| Median (IQR) | 3 (1.75-3) | 3 (2-3) | .36 |
| ≥4 | 0 | 16 (21) | .20 |
| Prior ASCT | 1 (10) | 19 (25) | .44 |
| Time from apheresis to infusion, d | |||
| Median (IQR) | 44 (41-54.8) | 41 (36-49) | .15 |
| Bridging therapy | 10 (100) | 71 (92) | >.99 |
| CAR T-cell product | |||
| Tisa-cel | 8 (80) | 26 (34) | .01 |
| Axi-cel | 2 (20) | 45 (58) | — |
| CRS | |||
| All grade | 10 (100) | 66 (86) | .34 |
| Grade 3 | 0 | 3 (4) | >.99 |
| ICANS | |||
| All grades | 5 (50) | 21 (27) | .16 |
| Grade ≥3 | 1 (10) | 2 (3) | .31 |
| Tocilizumab | 10 (100) | 49 (64) | .03 |
| Steroids | 6 (60) | 30 (39) | .31 |
| . | mHLA-DR <13 500 Ab/c (n = 10) . | mHLA-DR ≥13 500 Ab/c (n = 77) . | P∗ . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 60 (48-74) | 60 (27-77) | .02 |
| Mean (95% CI) | 65.5 (59.1-71.3) | 56.6 (53.9-59.3) | |
| >65 | 7 (70) | 21 (27) | .01 |
| Sex | |||
| Male sex | 7 (70) | 46 (60) | .73 |
| Female sex | 3 (30) | 31 (40) | — |
| Cell of origin | |||
| GCB | 6 (60) | 35 (56) | >.99 |
| Non-GCB | 4 (40) | 27 (44) | |
| B symptoms | 3 (30) | 6 (8) | .07 |
| ECOG PS | |||
| 0-1 | 5 (50) | 67 (87) | .01 |
| 2-3 | 5 (50) | 10 (13) | |
| Ann Arbor stage | |||
| I-II | 0 | 19 (25) | .11 |
| III-IV | 10 (100) | 58 (75) | |
| MTV D−7, mL | |||
| Median (IQR) | 114.4 (76.1-696.6) | 35.6 (5.8-116.7) | .02 |
| >80 mL | 5 (83) | 14 (30) | .02 |
| >100 mL (reported in JULIET trial) | 3 (50) | 13 (28) | .35 |
| LDH | |||
| >ULN | 9 (90) | 49 (64) | .15 |
| >2 ULN | 7 (70) | 5 (5) | <.0001 |
| Lines of therapy before leukapheresis, n | |||
| Median (IQR) | 3 (1.75-3) | 3 (2-3) | .36 |
| ≥4 | 0 | 16 (21) | .20 |
| Prior ASCT | 1 (10) | 19 (25) | .44 |
| Time from apheresis to infusion, d | |||
| Median (IQR) | 44 (41-54.8) | 41 (36-49) | .15 |
| Bridging therapy | 10 (100) | 71 (92) | >.99 |
| CAR T-cell product | |||
| Tisa-cel | 8 (80) | 26 (34) | .01 |
| Axi-cel | 2 (20) | 45 (58) | — |
| CRS | |||
| All grade | 10 (100) | 66 (86) | .34 |
| Grade 3 | 0 | 3 (4) | >.99 |
| ICANS | |||
| All grades | 5 (50) | 21 (27) | .16 |
| Grade ≥3 | 1 (10) | 2 (3) | .31 |
| Tocilizumab | 10 (100) | 49 (64) | .03 |
| Steroids | 6 (60) | 30 (39) | .31 |
ASCT, autologous stem cell transplantation; GCB, germinal center B cell; IQR, interquartile range; ULN, upper limit of normal.
Comparisons were performed by Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables. Bold indicates statistical significance.